Oct 17, 2017 — Accelerate Diagnostics, Inc. will announce third quarter 2017 financial results at the close of U.S. financial markets on Thursday, November 2, 2017. President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call that same day to review financial results and commercial progress at 4:15 p.m. ET. […]
Accelerate Diagnostics Welcomes Dr. Romney Humphries as Chief Scientific Officer
Jul 31, 2017 — TUCSON, Ariz., July 31, 2017 (GLOBE NEWSWIRE) – Accelerate Diagnostics, Inc. announced today the addition of Romney Humphries, PhD, D(ABMM), M(ASCP) to its executive management team as Chief Scientific Officer. Dr. Romney Humphries comes to Accelerate from UCLA Medical Center where she was the Section Chief for Clinical Microbiology and the Assistant Clinical Professor of […]
New data now available on the speed, accuracy and advantages of the Accelerate Pheno™ system
Jun 15, 2017 — TUCSON, Ariz., (June 14, 2017) — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The data comes from external studies across 11 healthcare institutions representing 1,300 samples, and compares the performance […]
Accelerate Diagnostics announces sizeable release of data at ASM Microbe 2017
May 30, 2017 — Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology – ASM Microbe in New Orleans, LA.
See all news
Enter your email address below for access to photos, logos and videos.
Connect with us
October 4–8, 2017
Stay up to date with Accelerate by joining our mailing list.Sign up today
June 1–5, 2017
May 10–13, 2017
Friday, May 5, 2017
April 22–25, 2017
March 26–28, 2017
March 21–27, 2017
Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.
These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.
Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.
See product labeling for instructions for use, warnings, and limitations specific to each product and region.Okay, I understand. Show me the publications.